scholarly journals Expression of the H-subunit and L-subunit of ferritin in bone marrow macrophages and cells of the erythron during cellular immune activation

2011 ◽  
Vol 47 (1) ◽  
pp. 50-55 ◽  
Author(s):  
A.M. Koorts ◽  
P.F. Levay ◽  
A.N. Hall ◽  
C.F. van der Merwe ◽  
P.J. Becker ◽  
...  
2020 ◽  
Vol 7 (2) ◽  
pp. 191825 ◽  
Author(s):  
James P. Higham ◽  
Christiane Stahl-Hennig ◽  
Michael Heistermann

Studies of large free-ranging mammals incorporating physiological measurements typically require the collection of urine or faecal samples, due to ethical and practical concerns over trapping or darting animals. However, there is a dearth of validated biomarkers of immune activation and inflammation that can be measured non-invasively. We here evaluate the utility of urinary measurements of the soluble form of the urokinase plasminogen activator receptor (suPAR), for use as a health marker in studies of wild large mammals. We investigate how urinary suPAR concentrations change in response to viral infection and surgical trauma (inflammation), comparing it to the measurement of a marker of cellular immune activation, urinary neopterin (uNEO), in captive rhesus macaques. We then test the field utility of urinary suPAR, assessing the effects of soil and faecal contamination, sunlight, storage at different temperatures, freeze–thaw cycles, and lyophilization. We find that suPAR concentrations rise markedly in response to both infection and surgery-associated inflammation, unlike uNEO concentrations, which only rise in response to the former. Our field validation demonstrates that urinary suPAR is reasonably robust to many of the issues associated with field collection, sample processing, and storage, as long as samples can be stored in a freezer. Urinary suPAR is thus a promising biomarker applicable for monitoring various aspects of health in wild primates and potentially also other large mammals.


2021 ◽  
Vol 22 (6) ◽  
pp. 1111-1120
Author(s):  
I. A. Goldina ◽  
E. V. Markova ◽  
I. A. Orlovskaya ◽  
L. B. Toporkova ◽  
V. A. Kozlov

Our aim was to evaluate immunomodulatory properties of an original bioflavonoid complex in experimental immune disturbances induced by cyclophosphamide (Cy). We have studied morphometric indexes of thymus and spleen, as well as blood leukocyte counts, cell proliferative activity in lymphoid organs, delayed hypersensitivity responses to T cell-dependent antigen, along with differentiation activity of bone marrow stem cells in experimental animals during Cy-induced immune suppression after a course of bioflavonoid treatment. Suspension of the bioflafonoid complex was introduced to the male mice (СВАхC57Bl/6)F1 aged 12- 14 weeks at a daily dose of 2 mg/animal (80 mg/kg), per os, using gastric catheter, over 14 days. Cytostatic immunosuppression was produced by a single intraperitoneal Cy injection. Proliferative activity of spleen and thymic cells was determined by standard method with Н3 -thymidine incorporation in the 72-h cell culture. Cellular immune response was assayed by the degree of delayed-type hypersensitivity development in response to sheep erythrocytes. The number of hematopoietic progenitors was evaluated by culturing bone marrow cells in methylcellulose-based medium. The experiments have shown mitigation of immunosuppressive effects induced by Cy, in the course of bioflavonoid complex treatment, with respect to absolute and relative mass of lymphoid organs and leukocyte numbers in peripheral blood. Moreover, we have demonstrated decreased effects of Cy treatment upon the spontaneous activity of spleen cells, mitogen-induced thymocyte and splenocyte proliferation, intensivity of delayed-type hypersensitivity response that reached the values of intact animals. Following the course of bioflavonoids, we have revealed an increase in early hematopoietic progenitors. Alleviation of Cy-induced suppressive effects upon cellular immune response, proliferation rates of immune cells, as well as stimulation of hematopoietic stem cell functions suggest a sufficient capacity of the original bioflavonoid complex for modulation of immunity and hematopoiesis, thus presenting experimental proofs for its potential usage as an adjuvant treatment of the patients with malignant diseases.


2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Cristina Oliveira ◽  
Sérgio Chacim ◽  
Isabel Ferreira ◽  
Nelson Domingues ◽  
José Mário Mariz

Hemophagocytic syndrome is a rare and potentially fatal disorder characterized by pathological immune activation associated with a primary familial disorder, genetic mutations, or occurring as a sporadic condition. The latter can be secondary to infections, malignancies, or autoimmune diseases. Clinically, patients present signs of severe inflammation, with unremitting fever, cytopenias, spleen enlargement, phagocytosis of bone marrow elements, hypertriglyceridemia, and hypofibrinogenemia. Increased suspicion is determinant to timely initiate treatment in an attempt to alter the natural history. The authors present three clinical cases of this syndrome, with a brief review of the diagnostic criteria and treatment.


2020 ◽  
Vol 2 (8) ◽  
pp. 3494-3506
Author(s):  
Dong-qun Liu ◽  
Shuai Lu ◽  
Lun Zhang ◽  
Ling-xiao Zhang ◽  
Mei Ji ◽  
...  

Schematic illustration of the LDH nanoparticle-coated yeast shell vaccine and immune activation.


1988 ◽  
Vol 24 (2) ◽  
pp. 289-289 ◽  
Author(s):  
Dietmarch Fuchs ◽  
Ernst R. Werner ◽  
Manfred P. Dierich ◽  
Helmut Wachter

2019 ◽  
Vol 4 (3) ◽  
pp. 291-300 ◽  
Author(s):  
Agnes Koczo ◽  
Amy Marino ◽  
Arun Jeyabalan ◽  
Uri Elkayam ◽  
Leslie T. Cooper ◽  
...  

2015 ◽  
Vol 112 (15) ◽  
pp. 4719-4724 ◽  
Author(s):  
Anita K. McElroy ◽  
Rama S. Akondy ◽  
Carl W. Davis ◽  
Ali H. Ellebedy ◽  
Aneesh K. Mehta ◽  
...  

Four Ebola patients received care at Emory University Hospital, presenting a unique opportunity to examine the cellular immune responses during acute Ebola virus infection. We found striking activation of both B and T cells in all four patients. Plasmablast frequencies were 10–50% of B cells, compared with less than 1% in healthy individuals. Many of these proliferating plasmablasts were IgG-positive, and this finding coincided with the presence of Ebola virus-specific IgG in the serum. Activated CD4 T cells ranged from 5 to 30%, compared with 1–2% in healthy controls. The most pronounced responses were seen in CD8 T cells, with over 50% of the CD8 T cells expressing markers of activation and proliferation. Taken together, these results suggest that all four patients developed robust immune responses during the acute phase of Ebola virus infection, a finding that would not have been predicted based on our current assumptions about the highly immunosuppressive nature of Ebola virus. Also, quite surprisingly, we found sustained immune activation after the virus was cleared from the plasma, observed most strikingly in the persistence of activated CD8 T cells, even 1 mo after the patients’ discharge from the hospital. These results suggest continued antigen stimulation after resolution of the disease. From these convalescent time points, we identified CD4 and CD8 T-cell responses to several Ebola virus proteins, most notably the viral nucleoprotein. Knowledge of the viral proteins targeted by T cells during natural infection should be useful in designing vaccines against Ebola virus.


Sign in / Sign up

Export Citation Format

Share Document